ESC 365 - A shorter duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials

ESC2025 Premium Access

A shorter duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials

Session: Adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

Topic: Adjunctive Pharmacotherapy

Speaker: Doctor T. Fretz (Indianapolis, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Thomas Fretz

Indiana University School of Medicine, Indianapolis (United States of America)

0 follower

4 more presentations in this session

State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

Speaker: Professor D. Capodanno (Catania, IT)

Impact of antiplatelet pretreatment on stent thrombosis in patients undergoing PCI in real world practice: insight France PCI registry

Speaker: Doctor G. Range (Chartres, FR)

Aspirin reloading before percutaneous coronary intervention on chronic aspirin therapy: reduced early ischemia without bleeding trade-off

Speaker: Doctor W. Dai (Tianjin, CN)

12- vs. 1-month DAPT: comparative outcomes after aspirin cessation with HT supreme stent

Speaker: Doctor T. Tsai (Taipei, TW)

Access the full session

Adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

Speakers: Doctor T. Fretz, Professor D. Capodanno, Doctor G. Range, Doctor W. Dai, Doctor T. Tsai

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources